Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

The FDA approved a new indication for mavacamten, extending its approval to include certain pediatric patients with ...

A once-weekly GLP-1/glucagon dual agonist reduced body weight by up to 9.8% at 76 weeks for adults with type 2 diabetes and ...

After joining Instagram less than a year ago, Lara M. Jones, MD, has amassed 10,000 followers by sharing her clinical expertise and speaking up for those who cannot.“The possibilities of your reach ...

But, you know, as a structural heart disease operator, you know, really over the last decade, I've been witness to TAVR just ...

Good news is, is that many patient groups are benefiting from TAVR in specific. Thinking about how the studies have changed, ...

Addition of a “simple” clinical risk score on top of current risk assessment tools may improve identification of patients ...

So it's important to try to understand what personalized treatment really means. And, you know, rather than just be a term ...

The FDA has issued a final rule that would remove references to animal studies in its drug safety regulations, as part of a ...

Heart disease is the No. 1 killer of women yet most treatments are based on male studies (image: Two-thirds of patients with Alzheimer’s disease are women yet it is unknown why (image: ...

A high level of physical activity was associated with less severe psoriasis, according to a study published in the Journal of the American Academy of Dermatology. These findings were consistent ...

A noninvasive neurosurgical procedure that delivers radiation to a specific brain pathway significantly reduced symptoms of major depression among people with severe, treatment-resistant psychiatric ...